Join us as we return to New York on June 5 to collaborate with leaders to explore comprehensive methods for auditing AI models for bias, performance, and ethical compliance in diverse organizations. Find out how you can attend here.
Health Atroposa healthcare technology company focused on generating personalized, real-world evidence, today announced that it has raised $33 million in Series B funding round. The round included strategic investments from healthcare giants McKesson, Merck and Cencora Ventures, signaling strong industry interest in Atropos' mission to bring high-quality, automated evidence to patient care decisions .
The Silicon Valley-based startup plans to use the new capital to expand its operations and double down on key initiatives such as launching into life sciences, expanding distribution partnerships in value-based care and l oncology, and the expansion of its network of evidence partners.
“Our mission is to bring personalized evidence of care to everyone in the world. So this is another step in this journey,” said Brigham Hyde, PhD, CEO and co-founder of Atropos Health, in an interview with VentureBeat. “Specifically, we will use this to double down on our strategic initiatives, which include continuing our launch into life sciences and leveraging the strong traction we have there, as well as strengthening our channel partners, particularly in value-based care and specialties. oncology care.
Shaping the future of healthcare delivery through AI-driven clinical evidence generation
The core technology of Atropos, Geneva OS, uses AI and automation to quickly generate clinical-quality evidence from real-world data. Developed over nearly a decade of research at Stanford, Geneva OS powers applications such as Atropos' generative AI assistant. CatRWD. The platform allows clinicians, researchers and others in the healthcare industry to quickly access reliable, personalized clinical evidence for specific patient populations – something the company says is lacking in today's the field of health care.
“We're talking about a concept called lack of evidence,” Hyde explained. “The statistic we have is that only about 14% of everyday medical decisions are supported by high-quality evidence. This is quite shocking if you are not in our fields. But the reasons for this are known: publications in the literature are driven by clinical trials, we are not conducting enough trials… What if we could use high quality data, analyzed correctly and accurately, to fill this lack of evidence?
Bridging the evidence gap: personalized information for better patient outcomes
Bridging this “evidence gap” is at the heart of Atropos’ mission. The company believes that providing clinicians with easy access to personalized evidence based on patients similar to the one in front of them will lead to better outcomes. Hyde gave the example of a doctor treating a patient with heart failure:
“We have diverse patient populations, they often have different comorbidities and backgrounds,” he said. “What you really need is clear evidence for these subpopulations – evidence that may not yet exist in the literature or in clinical trials… Let's not treat all patients with heart failure in the same way. Let's find the evidence for certain subgroups that generate better outcomes and control costs for these patients.
Accelerating pharmaceutical R&D through automation of real-world evidence
Applications of Atropos' technology also extend beyond point-of-care clinical decision-making. The company has partnered with pharmaceutical giants like Janssen accelerate drug development by generating evidence to inform clinical trial design, patient recruitment, and more. Hyde suggested the platform could even be used to simulate clinical trials.
“What if we had the ability to get evidence and information earlier to accelerate your trial design and development,” Hyde told VentureBeat. “What if we could recruit more effectively because we have this information and more trials are successful?” What if we could even simulate clinical trials and know in advance which ones are likely to succeed or not? All of this aims to reduce the length of the R&D cycle and reduce the risks of clinical trials.
Atropos’ Series B comes at a time of growing interest in the application of generative AI to specialized areas like healthcare. But Hyde believes that building trust through methodological rigor and transparency will be key to success.
“While there has been a lot of excitement around LLMs, frankly, a lot of it concerns us because we worry about hallucination rates,” he said. “Geneva guarantees that there are no hallucinations, that it is clinical quality, that it is incredibly transparent – a decade of publications on how it is done – and that users can trust what comes out.”
With new capital and a roster of leading strategic funders, Atropos is well-positioned to bring its vision of personalized and automated clinical evidence to healthcare on a global scale. But Hyde stressed that this is only the beginning:
“I think evidence is the currency of value in health care… What if I could provide (doctors) more evidence, and more personalized evidence, so they make a better decision?” Hyde applied. “Fundamentally, we are trying to move the world to a point where all patients and providers have access to personalized, quality evidence for their decision-making. »